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Introduction
Due to implementation of colorectal cancer screening pro-
grams, detection of submucosal invasive colorectal cancers
(T1-CRCs) has increased [1, 2], with additional opportunities
for local excisions.
Based on several pathological criteria, T1-CRCs can be divid-
ed into low risk or high risk for residual intramural cancer or
lymph node metastases (LNM). However, there is variation be-
tween models using various pathological criteria contributing
to a high-risk status (▶Table 1). Availability of these significant-
ly different models could lead to practice variation. In high-risk
T1-CRC, adjuvant oncological resection should be discussed
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ABSTRACT
Background and study aims Based on pathology, locally
resected T1 colorectal cancer (T1-CRC) can be classified as
having low- or high-risk for irradicality and/or lymph node
metastasis, the latter requiring adjuvant surgery. Reporting
and application of pathological high-risk criteria is likely
variable, with inherited variation regarding baseline oncolo-
gical staging, treatment and surveillance.
Methods We assessed practice variation using an online
survey among gastroenterologists and surgeons participat-
ing in the Dutch T1-CRC Working Group.
Results Of the 130 invited physicians, 53% participated.
Regarding high-risk T1-CRC criteria, lymphangio-invasion
is used by 100%, positive or indeterminable margins by
93%, poor differentiation by 90%, tumor-free margin
≤1mm by 78%, tumor budding by 57% and submucosal in-
vasion >1000µm by 47%. Fifty-two percent of the respon-
dents do not perform baseline staging in locally resected
low-risk T1-CRC. In case of unoperated high-risk patients,
we recorded 61 different surveillance strategies in 63 parti-
cipants, using 19 different combinations of diagnostic
tests. Endoscopy is used in all schedules. Mean follow-up
time is 36 months for endoscopy, 26 months for rectal MRI
and 30 months for abdominal CT (all varying 3–60 months).
Conclusion We found variable use of pathological high-
risk T1-CRC criteria, creating risk for misclassification as
low-risk T1-CRC. This has serious implications, as most par-
ticipants will not proceed to oncological staging in low-risk
patients and adjuvant surgery nor radiological surveillance
is considered. On the other hand, oncological surveillance
in patients with a locally resected high-risk T1-CRC who do
not wish adjuvant surgery is highly variable emphasizing
the need for a uniform surveillance protocol.
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with the patient. On the other hand, in low-risk T1-CRC, base-
line oncological staging is often considered unnecessary, as is
additional oncological resection, due to a very low recurrence
rate of 0.8% [3–5]. As a consequence, (mis)classification as
low-risk has important implications for the patient.
In patients with high-risk T1-CRC, there is an increasing
trend towards “wait and see” with surveillance chosen by the
patient on the basis of shared decision-making. This is because
risk of residual cancer in the bowel wall and lymph node metas-
tasis is 3% to 8% [3, 6–8] and 12% to 16% [4–6], respectively.
Accordingly, more than 84% of these patients have additional
surgery without clear benefit while being exposed to surgical
risks of morbidity (20%–30%), ostomy (5%–10%), and mortal-
ity (2.5%) [9, 10]. However, no guideline is available with advice
on a specific oncological surveillance strategy as an alternative
for these patients [11].
Various definitions and applications of pathological high-risk
criteria may contribute to practice variation with potential con-
sequences for treatment, baseline oncological staging, and sur-
veillance of patients after local excision of T1-CRC. We investi-
gated variations in personal daily practice about T1-CRC among
dedicated gastroenterologists and surgeons.
Methods
Survey development and participants
We developed a structured online survey regarding current
clinical practice of patients after local excision of a T1 CRC,
with the focus on four main topics: use of pathological high-
risk criteria, baseline oncological staging before local excision
of suspected T1-CRC, oncological staging after local excision
and surveillance of unoperated high-risk T1-CRC patients. The
patient’s situation was only globally addressed in the survey,
for instance as a hypothetical patient, being fit for surgery, but
we could not focus on individual patient details as this would
render the survey impractical to fill out and difficult to analyze.
This study was not intended to provide statistics on the type of
local excision and the occurrence of rectal versus colonic loca-
tions. We asked the participants to answer the questions ac-
cording to their own habits, which usually included counseling
of the multidisciplinary oncological meeting. The survey con-
sisted of 15 multiple choice and two open questions with exam-
ples of clinical cases (supplementary Appendix), based on
guidelines and gastroenterologist’s expert opinion.
The survey was published as a Google Form between January
and February 2019 and tested and improved by dedicated gas-
troenterologists for applicability, clarity and content. We col-
lected data on demographics of participants and their insti-
tutes, but no data which could identify the participant or the
center of employment to guarantee anonymity. Participants re-
ceived an e-mail with a cover letter and a link to the online sur-
vey, with a reminder after 2 weeks. Responses were accepted
up to 4 weeks from the initial e-mail. Participants comprised
all gastroenterologists and surgeons who are members of the
Dutch T1 CRC Working group. This is a group of Dutch specia-
lists in the field of T1 CRC, with joint research efforts and regu-
lar meetings.
Because the survey was based on voluntary participation and
information disclosure, the study protocol did not need to un-
dergo a formal review by an Ethics Committee. Survey return
was taken as consent.
Follow-up investigations were grouped as: carcinoembryo-
nic antigen (CEA); endoscopy; perirectal imaging (rectal endo-
ultrasonography and magnetic resonance imaging [MRI]); ab-
dominal lymph node imaging (abdominal computed tomog-
raphy [CT] scan); liver imaging (abdominal CT scan or liver ul-
trasound) and lung imaging (chest x-ray and thoracic CT scan).
Statistics
We used descriptive statistics to analyze the results using
counts and proportions for categorial data and means and
standard deviations for continuous variables. Missing values
were not imputed. The answers to most questions regarding
stage determination and surveillance were tested against the
type of hospital, specialty, age group and gender using chi-
square. Statistical analysis was performed with IBM SPSS ver-
sion 25.
Results
The survey was sent to 130 physicians and returned by 69 (53%
participation grade). ▶Table 2 lists baseline characteristics of
the participants. Eighty-seven percent of the participants were
gastroenterologists (60/69), 16% were employed in an aca-
demic center. Ninety-six percent of physicians reported dis-



















Dutch guideline [11] x x x uncertain
Scottish model [12] x x
French model [13] x x x
Japanese guideline [14] x x x x x
“x” confers high-risk status.
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cussing every patient with a T1 CRC in a regular multidisciplin-
ary oncological meeting. Only 21 of 69 (30%) of the physicians
reported having a local T1 CRC protocol available in their hospi-
tal.
Risk stratification
Pathological criteria used for low-risk or high-risk classification
are shown in ▶Fig. 1. Undisputed criteria for high risk in the
Netherlands are lymphovascular invasion, a resection margin
that is not free or indeterminable, and poor differentiation or
presence of signet cells [12]. Eighty-one percent of the respon-
dents used all three criteria. Tumor budding is not currently
standardly reported by pathology labs in the Netherlands and
was used by half of the respondents. Contribution of both a tu-
mor-free margin≤1mm and invasion depth to high-risk status
are disputed and were less often used. Fifty percent of aca-
demic participants did not use a tumor-free margin≤1mm as
a high-risk criterion, whereas 80% of non-academic specialists
did (P =0.044). The other criteria did not show significant dif-
ferences between academic and non-academic specialists.
Only twelve (17%) of the participants used the exact criteria
from the Dutch Guideline to determine high risk (▶Table 1)
[12]. The Scottish and French models [13, 14] were used by
none of the participants, the Japanese guideline [15] by five
(7.2%).
Baseline oncological staging
In the example case of a macroscopically recognized carcinoma
during endoscopy, 13 (19%) would perform oncological staging
prior to local excision, whereas five (7%) would only do so in
case of rectal localization.
Of those who would not perform a priori staging (51 respon-
dents), 53% would stage every patient if pathology confirms a
T1-CRC (low-risk and high-risk), while 47% would do so only in
case of one or more high-risk features.
When confronted with an unexpected carcinoma (“oops”-
carcinoma) in a locally removed polyp, 49% would only stage
in case of high-risk features, the remainder in every case. We
examined associations between type of hospital, specialty,
sex, age groups, and baseline staging practices. No statistically
significant associations were found, although it was remarkable
that staging of suspected lesions before embarking on endo-
scopic resection was not performed by any of the nine aca-
demic respondents. Taken together, approximately 50% will
not perform baseline oncological staging in case of locally re-
sected low-risk T1-CRC.
Surveillance after locally resected high-risk T1 CRC
in patients who refrain from additional surgery
Details about surveillance strategies were returned by 63 parti-
cipants; most participants (84%) indicated using the same sur-
veillance strategies after local excision of T1 CRC by submuco-
sal dissection or full-thickness local resection techniques (such
as trans-anal endoscopic microsurgery, or endoscopic full-
thickness resection). On closer look, we encountered 61 differ-
ent schedules, with 19 different combinations of diagnostic
tests. Endoscopy is used in all schedules. Endoscopic surveil-
lance has a median duration of 48 months (IQR 24–48 months).
Radiological surveillance (including rectal endoultrasonogra-
phy) has a median duration of 36 months (IQR 12–48 months),
and CEA monitoring time has a median duration of 48 months
(IQR 24–48 months). A heat map of the time points and follow-
up investigations is shown in ▶Fig. 2. Significant differences
Criterion
Lymphovascular invasion 100 %
Resection margin not free/indeterminable 93 %
Poorly diff erentiated or signet-cell 
containing adenocarcinoma 88 %
Free resection margin ≤ 1 mm 75 %
Tumor budding grade 2 or 3 55 %
Submucosal invasion depth > 1000 μm or 
sm3 invasion 49 %
▶ Fig. 1 Heat map of pathology criteria used by respondents to de-
fine risk status.
▶Table 2 Demographic characteristics of the participants.
Variable n (%)
Specialist
▪ Surgeon  8 (12%)
▪ Gastroenterologist 60 (87%)
▪ Physician Assistent gastroenterology  1 (1%)
Type of hospital
▪ University hospital 11 (16%)
▪ General hospital, < 6 gastroenterologists  6 (9%)
▪ General hospital, 6–10 gastroenterologists 34 (49%)
▪ General hospital, > 10 gastroenterologists 16 (23%)
▪ Private hospital  2 (3%)
Sex
▪ Male 49 (71%)
▪ Female 20 (29%)
Age group
▪ 30–40 years 21 (30%)
▪ 40–50 years 29 (42%)
▪ 50–60 years 15 (22%)
▪ >60 years  4 (6%)
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between academic and non-academic respondents are sum-
marized in ▶Fig. 3. In general, more follow-up investigations
are performed by academic specialists, with higher use of CT-
scans.
Most participants would proceed to surgery (n =50) when
local recurrence or suspicious lymphadenopathy is demonstrat-
ed during follow-up, six of them suggested also performing this
in case of limited metastasis, and two respondents in case of in-
creasing CEA levels.
Discussion
In this study, considerable practice variation among Dutch hos-
pitals was observed in risk classification used to predict lymph
node metastasis and local recurrence, on baseline oncological
staging and especially on follow-up after local excision of a T1
CRC with high-risk features, but while refraining from perform-
ing surgery.
It is well known that pathological criteria that contribute to a
high-risk status of a locally resected T1-CRC are subject to in-
terobserver variation by pathologists [16, 17]. Indeed, a sub-
stantial percentage of these lesions are reclassified as high risk
after revision by an expert pathologist [18]. However, in the
Netherlands, a decision about T1-CRC risk status is made by
the treating physician, and not by the pathologist, who merely
reports on presence or absence of these risk factors. Thus, it is
important to understand how treating physicians deal with this
information. In our survey, directed at specialists with special
interest in T1-CRC, we encountered considerable practice varia-
tion.
Previous studies show conflicting results concerning the
true value of submucosal invasion depth≥1000µm and a tu-
mor-free margin <1mm as a high-risk pathological factor [8,
19–23]. Indeed, this survey found that submucosal invasion
depth≥1000µm is used by 49% of physicians and a tumor-free
margin <1mm by 75%. Although lymphangio-invasion, poor
differentiation, and a positive or indeterminable resection mar-
gin are undisputed risk factors [6, 12, 19–22, 24–26], 19% of re-
spondents do not use all three criteria. In the literature, high-
Investigation targets. Liver imaging: abdominal CT and/or ultrasound; perirectal imaging: pelvic MRI or rectal endosonography; lung imaging: chest 
X-ray or CT thorax; Abdominal lymph node imaging: abdominal CT.
Month 3 6 12 18 24 30 36 42 48 54 60
Endoscopy 67 % 76 % 83 % 33 % 52 % 13 % 37 % 11 % 46 % 2 % 11 %
Liver imaging 19 % 49 % 65 % 21 % 56 %  6 % 41 %  6 % 41 % 14 %
Perirectal imaging 35 % 49 % 56 % 22 % 38 % 11 % 29 %  8 % 25 %  2 % 13 %
Serum CEA 29 % 48 % 52 % 29 % 45 % 14 % 38 % 11 % 37 %  2 %  9 %
Lung imaging  9 % 27 % 27 %  6 % 27 %  2 % 25 %  2 % 23 %  6 %
Abdominal lymph node imaging 17 % 24 % 38 % 10 % 25 %  2 % 16 %  3 % 19 % 10 %
▶ Fig. 2 Heat map of investigation targets.





Endoscopy 18 67 % 28 % 0.022
Pelvic MRI 42 22 %  2 % 0.008
48 56 % 15 % 0.005
CT abdomen 24 56 % 20 % 0.025
30 11 %  0 % 0.014
42 22 %  0 % 0.000
48 44 % 15 % 0.036
CT thorax 24 22 %  2 % 0.008
30 11 %  0 % 0.014
36 22 %  2 % 0.008
42 11 %  0 % 0.008
48 22 %  2 % 0.008
X-ray thorax 18 22 % 0 % 0.000
CEA 42 33 %  7 % 0.019
Perirectal imaging 48 56 % 20 % 0.025
Liver imaging 24 89 % 50 % 0.030
42 22 %  4 % 0.035
48 78 % 35 % 0.016
Lung imaging  6 56 % 22 % 0.034
18 33 %  2 % 0.000
24 56 % 24  % 0.034     
30 11 %  0 % 0.013
42 11 %  0 % 0.013
48 56 % 18 % 0.014
Time point is in months. MRI, magnetic resonance imaging; 
CT, computed tomography;  CEA, carcinoembryonic antigen
▶ Fig. 3 Significant differences between academic and non-aca-
demic specialists in surveillance time points and investigations
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grade tumor budding is a strong risk factor as well [19–21, 26],
but this criterion was used by half of the respondents. This is
probably explained by the fact that, in the Netherlands, report-
ing of tumor budding is currently not obligatory.
Taken together, incomplete use of pathological high-risk
factors carries the risk of wrong low-risk classification of a local-
ly resected T1-CRC.
Misclassification as low-risk T1-CRC has important conse-
quences. Our study showed that half the physicians do not per-
form baseline oncological staging in these patients (which is
theoretically defensible as risk of metastasized disease in true
low-risk T1-CRC is only 0.8% [3–5]).
In addition, the option of adjuvant surgical resection will not
be discussed in low-risk T1-CRC and surveillance is only per-
formed according to the current polyp surveillance guideline
using merely colonoscopy [27].
In the second part of the survey, we addressed surveillance
practices of physicians in patients after local excision of a
high-risk T1-CRC without adjuvant surgery.
We found enormous practice variation among physicians,
which underscores the need for a uniform surveillance proto-
col.
We recognize, however, that such a protocol is difficult to
conceive. Literature on surveillance of unoperated high-risk
T1-CRC is scanty and retrospective. Asian studies describe use
of CEA and thoraco-abdominal CT every 6 months for 3 years,
thereafter every 12 months for 2 years, combined with annual
colonoscopy [4, 28]. A less invasive strategy with CEA, CT of the
chest, abdomen, and pelvis, and a colonoscopy every year for 5
years was used by Kouyama et al [25]. However, the benefit of
these surveillance strategies has not been established. In
particular, baseline radiological oncological staging of lymph
nodes in colorectal cancer is hampered by moderate sensitivity
and specificity of approximately 75% [29–36], and there exists
no literature on the benefits of sequential imaging over time.
Our study has some limitations.
1. Only physicians participating in the T1-CRC working group
were invited, which may create response bias towards ex-
perts in the field of T1-CRC. Accordingly, the reader should
be aware of the fact that application of pathological high-
risk criteria may be more incomplete in less involved physi-
cians.
2. It should be noted that only some of the questions addres-
sed the rectum and colon separately. Although this had no
influence on our findings regarding application of patholog-
ical high-risk criteria and oncological staging, surveillance
strategies differed between these tumor locations.
3. Each respondent provided his or her own opinion. Although
reflecting the usual outcome of the multidisciplinary oncol-
ogy meetings of the local hospital was encouraged, it is
possible that the actual advice from a multidisciplinary
meeting would have been different from the answers
provided by the respondents. Nevertheless, the answers do
reflect an overview of the respondents’ personal habits.
4. We limited patient details in our questionnaires to the most
important to improve generalization, for instance “fit for
surgery,” while realizing that patient-specific additional fac-
tors will play a role in daily practice.
Conclusion
In conclusion, we encountered considerable practice variation
with regard to use of pathological high-risk T1-CRC criteria,
with potential misclassification as low-risk T1-CRC. This has ser-
ious consequences, as a lot of these patients will not have base-
line oncological staging and counseling about adjuvant sur-
gery, or radiological surveillance. For the growing group of pa-
tients who do not wish to have adjuvant surgery in case of local-
ly resected high-risk T1-CRC, a standardized oncological sur-
veillance protocol is urgently needed.
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